In vivo gene therapy with CAR-T cells
Generating CAR-T cells directly inside patients' bodies could make this powerful cancer treatment more affordable and easier to access.
This review in Blood summarizes emerging clinical evidence for in vivo CAR-T cell generation, where the CAR-T cells are generated directly within the patient's body rather than through complex ex vivo manufacturing. The approach offers a potential solution to the access and cost limitations of conventional CAR-T therapy, with first clinical reports demonstrating feasibility and antitumor activity.
What the study was
- Study design
- Review with clinical proof-of-concept data summary
- Population
- Patients with lymphoid hematologic malignancies
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Blood
Why it surfaced
In vivo CAR-T represents a transformative potential approach to overcome the major access/cost barriers of conventional CAR-T therapy. First clinical proof-of-concept now reported. Blood journal, leading CAR-T researchers (Maus, Wagner). Elevated to HIGH by NOVEL_TREATMENT flag despite review design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.